SLC9A2: A Protein Implicated in A Variety of Human Physiological Processes

Target Name: SLC9A2

NCBI ID: G6549

SLC9A2

SLC9A2: A Protein Implicated in A Variety of Human Physiological Processes

SLC9A2 (NHE-2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the NHE gene family, which encodes a family of transport proteins that play a critical role in the regulation of intracellular fluids and electrolytes.

SLC9A2 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is a member of the NHE gene family, which encodes a family of transport proteins that play a critical role in the regulation of intracellular fluids and electrolytes. SLC9A2 is a widely expressed protein, and is found in various tissues throughout the body.

SLC9A2 is involved in the regulation of a variety of physiological processes that are critical to human health, including the regulation of ion and water balance, and the regulation of the blood pressure. It is also involved in the regulation of neurotransmitter release and the modulation of pain perception.

SLC9A2 has been shown to play a critical role in the development and progression of a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. It is also involved in the development of certain cardiovascular conditions, such as hypertension and heart failure.

SLC9A2 is a potential drug target, and is being studied for its potential therapeutic uses in a variety of conditions. For example, SLC9A2 has been shown to be involved in the regulation of pain perception, and is being studied as a potential therapeutic for the treatment of chronic pain. Additionally, SLC9A2 is involved in the regulation of neurotransmitter release, and is being studied as a potential therapeutic for the treatment of depression and anxiety disorders.

SLC9A2 is also a potential biomarker for a variety of conditions, including neurological and psychiatric disorders. For example, SLC9A2 has been shown to be involved in the regulation of the levels of certain neurotransmitters, such as dopamine and serotonin, and is being studied as a potential biomarker for the treatment of depression and anxiety disorders.

In conclusion, SLC9A2 is a protein that is involved in a variety of physiological processes that are critical to human health. It is a member of the NHE gene family and is widely expressed in various tissues throughout the body. SLC9A2 is involved in the regulation of ion and water balance, the regulation of neurotransmitter release, and the regulation of pain perception. It is also involved in the development and progression of a variety of neurological and psychiatric disorders, and is a potential drug target and biomarker for a variety of conditions. Further research is needed to fully understand the role of SLC9A2 in human health and to develop effective therapies based on its properties.

Protein Name: Solute Carrier Family 9 Member A2

Functions: Plasma membrane Na(+)/H(+) antiporter. Mediates the electroneutral exchange of intracellular H(+) ions for extracellular Na(+) (PubMed:10444453). Major apical Na(+)/H(+) exchanger in the base of the colonic crypt. Controls in the colonic crypt intracellular pH (pHi) to direct colonic epithelial cell differentiation into the absorptive enterocyte lineage at the expense of the secretory lineage (By similarity)

The "SLC9A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC9A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets